Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Good Practices Report of an ISPOR Task Force.

[1]  J. Swait,et al.  The Role of Attribute Screening and Choice Set Formation in Health Discrete Choice Experiments: Modeling the Impact of Benefit and Risk Attributes. , 2022, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[2]  T. Tervonen,et al.  Multimethod quantitative benefit‐risk assessment of treatments for moderate‐to‐severe osteoarthritis , 2022, British journal of clinical pharmacology.

[3]  T. Tervonen,et al.  Comparing Patient Preferences for Antithrombotic Treatment During the Acute and Chronic Phases of Myocardial Infarction: A Discrete-Choice Experiment , 2021, The Patient - Patient-Centered Outcomes Research.

[4]  Leila G. Lackey,et al.  Applying Decision Analysis to Inform the US Food and Drug Administration's Benefit-Risk Assessment of Ticagrelor for Primary Prevention of Myocardial Infarction or Stroke Based on THEMIS. , 2021, Circulation.

[5]  K. Marsh,et al.  How to integrate evidence from patient preference studies into health technology assessment: a critical review and recommendations , 2021, International Journal of Technology Assessment in Health Care.

[6]  K. Marsh,et al.  Assessing Patient Preferences in Rare Diseases: Direct Preference Elicitation in the Rare Chronic Kidney Disease, Immunoglobulin A Nephropathy , 2021, The Patient - Patient-Centered Outcomes Research.

[7]  Shomesh E. Chaudhuri,et al.  Parkinson’s Patients’ Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique Study , 2021, MDM policy & practice.

[8]  F. Martinez,et al.  Dual-combination maintenance inhaler preferences in asthma and chronic obstructive pulmonary disease: A patient-centered benefit-risk assessment. , 2020, Respiratory medicine.

[9]  B. Donkers,et al.  What Factors Influence Non-Participation Most in Colorectal Cancer Screening? A Discrete Choice Experiment , 2020, The Patient - Patient-Centered Outcomes Research.

[10]  D. Street,et al.  Respondent Understanding in Discrete Choice Experiments: A Scoping Review , 2020, The Patient - Patient-Centered Outcomes Research.

[11]  K. Marsh,et al.  Quantitative Benefit–Risk Assessment: State of the Practice Within Industry , 2020, Therapeutic Innovation & Regulatory Science.

[12]  S. Pocock,et al.  The win ratio approach for composite endpoints: practical guidance based on previous experience. , 2020, European heart journal.

[13]  A. Dibernardo,et al.  Patient preferences for ketamine-based antidepressant treatments in treatment-resistant depression: Results from a clinical trial and panel , 2020 .

[14]  Yongjun Wang,et al.  Methodologies for pragmatic and efficient assessment of benefits and harms: Application to the SOCRATES trial , 2020, Clinical trials.

[15]  Bennett Levitan,et al.  Appraising patient preference methods for decision-making in the medical product lifecycle: an empirical comparison , 2020, BMC Medical Informatics and Decision Making.

[16]  Lawrence D Phillips,et al.  Advancing structured decision‐making in drug regulation at the FDA and EMA , 2020, British journal of clinical pharmacology.

[17]  S. Dy,et al.  Analysis of Patient Preferences in Lung Cancer – Estimating Acceptable Tradeoffs Between Treatment Benefit and Side Effects , 2020, Patient preference and adherence.

[18]  R. Willke,et al.  Criteria and Process for Initiating and Developing an ISPOR Good Practices Task Force Report. , 2020, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[19]  Toshimitsu Hamasaki,et al.  Analysis of ordered composite endpoints , 2019, Statistics in medicine.

[20]  L. Phillips,et al.  Quantifying Preferences in Drug Benefit‐Risk Decisions , 2019, Clinical pharmacology and therapeutics.

[21]  B. Levitan,et al.  Benefit–Risk Assessments of Medical Treatments , 2019, Pharmacoepidemiology.

[22]  K. Payne,et al.  A Picture is Worth a Thousand Words: The Role of Survey Training Materials in Stated-Preference Studies , 2019, The Patient - Patient-Centered Outcomes Research.

[23]  E. Eisenhauer,et al.  The Value of Progression-Free Survival as a Treatment End Point Among Patients With Advanced Cancer: A Systematic Review and Qualitative Assessment of the Literature. , 2019, JAMA oncology.

[24]  B. Hauber,et al.  Using the Threshold Technique to Elicit Patient Preferences: An Introduction to the Method and an Overview of Existing Empirical Applications , 2019, Applied Health Economics and Health Policy.

[25]  I. Huys,et al.  Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review. , 2019, Drug discovery today.

[26]  L. Prosser,et al.  Spillover Effects on Caregivers’ and Family Members’ Utility: A Systematic Review of the Literature , 2019, PharmacoEconomics.

[27]  F Reed Johnson,et al.  The Internal Validity of Discrete Choice Experiment Data: A Testing Tool for Quantitative Assessments. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[28]  A. Marson,et al.  Patient‐Focused Drug Development Methods for Benefit–Risk Assessments: A Case Study Using a Discrete Choice Experiment for Antiepileptic Drugs , 2018, Clinical pharmacology and therapeutics.

[29]  G. Prescott,et al.  Defining and measuring multimorbidity: a systematic review of systematic reviews , 2018, European journal of public health.

[30]  Alan R. Ellis,et al.  Discrete Choice Experiments in Health Economics: Past, Present and Future , 2018, PharmacoEconomics.

[31]  K. Marsh,et al.  Assessing Rationality in Discrete Choice Experiments in Health: An Investigation into the Use of Dominance Tests. , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[32]  G. Lip,et al.  Comparison of Oral Anticoagulants for Stroke Prevention in Nonvalvular Atrial Fibrillation: A Multicriteria Decision Analysis. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[33]  John F P Bridges,et al.  Improving the quality of discrete-choice experiments in health: how can we assess validity and reliability? , 2017, Expert review of pharmacoeconomics & outcomes research.

[34]  P. Kanavos,et al.  Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework. , 2017, Social science & medicine.

[35]  K. Marsh,et al.  MCDA swing weighting and discrete choice experiments for elicitation of patient benefit‐risk preferences: a critical assessment , 2017, Pharmacoepidemiology and drug safety.

[36]  D. Spiegelhalter.  Risk and Uncertainty Communication , 2017 .

[37]  A. Morton.  Treacle and Smallpox: Two Tests for Multicriteria Decision Analysis Models in Health Technology Assessment. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[38]  Anindita Saha,et al.  A Framework for Incorporating Patient Preferences Regarding Benefits and Risks into Regulatory Assessment of Medical Technologies. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[39]  Kei Long Cheung,et al.  Using Best–Worst Scaling to Investigate Preferences in Health Care , 2016, PharmacoEconomics.

[40]  T. Welte,et al.  Preferences of lung cancer patients for treatment and decision-making: a systematic literature review. , 2016, European journal of cancer care.

[41]  G. Raskob,et al.  Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-Extension. , 2016, Chest.

[42]  Maarten J. IJzerman,et al.  Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[43]  C. Dirksen,et al.  Survival or Mortality: Does Risk Attribute Framing Influence Decision-Making Behavior in a Discrete Choice Experiment? , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[44]  Shahrul Mt-Isa,et al.  Literature review of visual representation of the results of benefit–risk assessments of medicinal products , 2016, Pharmacoepidemiology and drug safety.

[45]  Zoltán Kaló,et al.  Multiple Criteria Decision Analysis for Health Care Decision Making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[46]  Shahrul Mt-Isa,et al.  Recommendations for benefit–risk assessment methodologies and visual representations , 2016, Pharmacoepidemiology and drug safety.

[47]  Peter Zweifel,et al.  Experimental measurement of preferences in health and healthcare using best-worst scaling: an overview , 2016, Health Economics Review.

[48]  Maarten J. IJzerman,et al.  Multiple Criteria Decision Analysis for Health Care Decision Making--An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[49]  Ortwin Renn,et al.  Structured Frameworks to Increase the Transparency of the Assessment of Benefits and Risks of Medicines: Current Status and Possible Future Directions , 2015, Clinical pharmacology and therapeutics.

[50]  A. Schuit,et al.  Preferences for Vaccination , 2015, Medical decision making : an international journal of the Society for Medical Decision Making.

[51]  S. Cosgrove,et al.  Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR). , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[52]  A. Ades,et al.  Applying Multiple Criteria Decision Analysis to Comparative Benefit-Risk Assessment , 2015, Medical decision making : an international journal of the Society for Medical Decision Making.

[53]  W. Ageno,et al.  Benefit–risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism , 2014, Thrombosis and Haemostasis.

[54]  A. Mühlbacher,et al.  Patients’ preferences: a discrete-choice experiment for treatment of non-small-cell lung cancer , 2014, The European Journal of Health Economics.

[55]  Caroline Vass,et al.  Risk as an Attribute in Discrete Choice Experiments: A Systematic Review of the Literature , 2014, The Patient - Patient-Centered Outcomes Research.

[56]  K. Marsh,et al.  Assessing the Value of Healthcare Interventions Using Multi-Criteria Decision Analysis: A Review of the Literature , 2014, PharmacoEconomics.

[57]  Telba Irony,et al.  Incorporating patient-preference evidence into regulatory decision making , 2014, Surgical Endoscopy.

[58]  Adem Sav,et al.  Treatment burden among people with chronic illness: what are consumer health organizations saying? , 2013, Chronic illness.

[59]  Deborah Marshall,et al.  Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[60]  Jonathan Karnon,et al.  Model Parameter Estimation and Uncertainty: a Report of the Ispor-smdm Modeling Good Research Practices Task Force-6 Background to the Task Forcemodel-parameter-estimation-and- Uncertainty-analysis.asp). a Summary of These Articles Was Pre- Sented at a Plenary Session at the Ispor 16th Annual Intern , 2022 .

[61]  John F P Bridges,et al.  Patients' preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis. , 2012, Lung cancer.

[62]  Andrew Hayen,et al.  The Influence of Graphic Display Format on the Interpretations of Quantitative Risk Information among Adults with Lower Education and Literacy , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.

[63]  Andrew Lloyd,et al.  Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[64]  Tommi Tervonen,et al.  A stochastic multicriteria model for evidence‐based decision making in drug benefit‐risk analysis , 2011, Statistics in medicine.

[65]  B S Levitan,et al.  Development of a Framework for Enhancing the Transparency, Reproducibility and Communication of the Benefit–Risk Balance of Medicines , 2011, Clinical pharmacology and therapeutics.

[66]  B S Levitan,et al.  Application of the BRAT Framework to Case Studies: Observations and Insights , 2011, Clinical pharmacology and therapeutics.

[67]  I. Lipkus.  Numeric, Verbal, and Visual Formats of Conveying Health Risks: Suggested Best Practices and Future Recommendations , 2007, Medical decision making : an international journal of the Society for Medical Decision Making.

[68]  Arne Risa Hole,et al.  A comparison of approaches to estimating confidence intervals for willingness to pay measures. , 2007, Health economics.

[69]  Emily Lancsar,et al.  Deleting 'irrational' responses from discrete choice experiments: a case of investigating or imposing preferences? , 2006, Health economics.

[70]  Erika A. Waters,et al.  Formats for Improving Risk Communication in Medical Tradeoff Decisions , 2006, Journal of health communication.

[71]  Nicola J Cooper,et al.  A Bayesian approach to evaluating net clinical benefit allowed for parameter uncertainty. , 2005, Journal of clinical epidemiology.

[72]  Ralph L. Keeney,et al.  Selecting Attributes to Measure the Achievement of Objectives , 2005, Oper. Res..

[73]  C. N. Coleman,et al.  CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. , 2003, Seminars in radiation oncology.

[74]  Ralph L. Keeney,et al.  Common Mistakes in Making Value Trade-Offs , 2002, Oper. Res..

[75]  G. Elwyn,et al.  Presenting risk information--a review of the effects of "framing" and other manipulations on patient outcomes. , 2001, Journal of health communication.

[76]  Ralph L. Keeney,et al.  Multiplicative Utility Functions , 1974, Oper. Res..